Ones To Watch News
Refine Search
Biotechnology
The European Commission (EC) has granted marketing authorization for China-headquartered biotech BeiGene’s Brukinsa (zanubrutinib) in combination with obinutuzumab for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma. 17 November 2023
Biotechnology
Boston, USA-based biotechnology start-up PostEra, which specializes in artificial intelligence for pre-clinical drug discovery, has entered into a multi-target collaboration with US biotech major Amgen. 17 November 2023
Biotechnology
US drug developer SpringWorks Therapeutics today announced what it described as positive top-line results from its Phase IIb ReNeu trial evaluating mirdametinib. 16 November 2023
Biotechnology
A new cell therapy company has launched in Cambridge, UK, with $59 million in series A funding provided by Sofinnova Partners and others, including Sanofi Ventures. 16 November 2023
Biotechnology
Adding to the collaboration agreed last December, Gilead Sciences’ subsidiary Kite has today announced it is expanding it collaboration with US biotech Arcellx. 15 November 2023
Biotechnology
Antibody specialist Nona Biosciences has entered into a strategic collaboration with Chinese bioconjugation company GeneQuantum Healthcare. 15 November 2023
Pharmaceutical
Markets have reacted warmly to a radical plan from Theseus Pharmaceuticals to cut costs and potentially put itself up for a sale or merger. 15 November 2023
Biotechnology
London-listed blood disease specialist Hemogenyx Pharmaceuticals has announced the successful completion of the re-manufacturing of an improved lentivirus (LVV) devoid of splice variants. 15 November 2023
Pharmaceutical
Swiss drugmaker Basilea Pharmaceutica has entered into an asset purchase agreement with Amplyx Pharmaceuticals to acquire the rights to fosmanogepix, a clinical-stage broad-spectrum antifungal candidate. 14 November 2023
Pharmaceutical
Autifony Therapeutics, an independent biotech company formed in 2011 as a spin-out from GSK, has announced a collaboration with Ireland-headquartered Jazz Pharmaceuticals. 14 November 2023
Biotechnology
Allergy Therapeutics today said that a trial evaluating the efficacy of its subcutaneous allergen-specific immunotherapy candidate has met its primary goal, with the news sending the UK biotech’s shares up 20.8% to 1.80 pence. 14 November 2023
Pharmaceutical
Boston, USA-based PureTech Health saw its London-listed share edge up 1.6% to 176.00 pence, after it announced top-line results from its Phase IIa, randomized, placebo-controlled, proof-of-concept trial of LYT-300 (oral allopregnanolone) in anxiety. 14 November 2023
Biotechnology
Cambridge, USA-based precision oncology firm Incendia Therapeutics today announced the appointment of Dr Wendye Robbins as chief executive (CEO). 13 November 2023
Biotechnology
Legend Biotech Corporation has entered into an exclusive, global license agreement with Swiss pharma giant Novartis. 13 November 2023
Biotechnology
Dutch biotech company VectorY Therapeutics today announced the close of a 129 million-euro ($138 million) Series A financing. 13 November 2023
Biotechnology
US neuroscience-focused biopharma Neurocrine Biosciences today announced that it has resolved all patent litigation related to lawsuits resulting from Abbreviated New Drug Applications (ANDAs) brought by companies seeking approval to market a generic version of Ingrezza (valbenazine) prior to the expiration of applicable Neurocrine patents. 13 November 2023
Pharmaceutical
UK-based Kelso Pharma today revealed it has taken its first step in its European expansion strategy by agreeing to acquire Italy’s Velit Biopharma which, like Kelso is a specialty pharma company. 13 November 2023
Pharmaceutical
US clinical-stage liver disease specialist Madrigal Pharmaceuticals’ shares gained 1.8% to $138.84 on Friday, as it announced new data from the Phase III MAESTRO-NASH trial demonstrating broad treatment effects of resmetirom. 13 November 2023
Biotechnology
Cambridge, UK-based drug discovery and development company Mission Therapeutics today announced the publication of a peer-reviewed article titled ‘Knockout or inhibition of USP30 protects dopaminergic neurons in a Parkinson’s disease (PD)’ in the journal Nature Communications. 13 November 2023
Pharmaceutical
Poolbeg Pharma has recruited three new members of its leadership team from Amryt Pharma, a fellow Anglo-Irish drugmaker with the same co-founder that was recently acquired by privately-held Italian drugmaker Chiesi. 10 November 2023
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Pharmaceutical
US biotech Corcept Therapeutics has reported positive results from the Phase IV CATALYST study of Korlym (mifepristone) in people with hypercortisolism and difficult-to-control type 2 diabetes. 13 December 2024
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Pharmaceutical
UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. 12 December 2024
Biotechnology
AI-driven biotech BenevolentAI has announced sweeping changes aimed at refocusing its operations and extending its financial runway into 2027. 12 December 2024
Biotechnology
USA-based Elevation Oncology, an innovative oncology company focused on the discovery and development of selective cancer therapies, has entered into a licensing agreement with Synaffix, part of Swiss out-sourcing major Lonza. 12 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze